Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

Article Type

Case Report


The two case studies presented in this article support the findings from a series of retrospective studies, which showed that urinary symptoms improved in women with overactive bladder syndrome who were receiving ospemifene for vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.